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NMR structure of an anti-gp120 antibody complex with a V3
peptide reveals a surface important for co-receptor binding
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Background: The protein 0.5β is a potent strain-specific human
immunodeficiency virus type 1 (HIV-1) neutralizing antibody raised against the
entire envelope glycoprotein (gp120) of the HIV-1IIIB strain. The epitope
recognized by 0.5β is located within the third hypervariable region (V3) of
gp120. Recently, several HIV-1 V3 residues involved in co-receptor utilization
and selection were identified.
Results: Virtually complete sidechain assignment of the variable fragment (Fv)
of 0.5β in complex with the V3IIIB peptide P1053 (RKSIRIQRGPGRAFVTIG, in
single-letter amino acid code) was accomplished and the combining site
structure of 0.5β Fv complexed with P1053 was solved using multidimensional
nuclear magnetic resonance (NMR). Five of the six complementarity determining
regions (CDRs) of the antibody adopt standard canonical conformations,
whereas CDR3 of the heavy chain assumes an unexpected fold. The epitope
recognized by 0.5β encompasses 14 of the 18 P1053 residues. The bound
peptide assumes a β-hairpin conformation with a QRGPGR loop located at the
very center of the binding pocket. The Fv and peptide surface areas buried
upon binding are 601 Å and 743 Å2, respectively, in the 0.5β Fv–P1053 mean
structure. The surface of P1053 interacting with the antibody is more extensive
and the V3 peptide orientation in the binding site is significantly different
compared with those derived from the crystal structures of a V3 peptide of the
HIV-1 MN strain (V3MN) complexed to three different anti-peptide antibodies.
Conclusions: The surface of P1053 that is in contact with the anti-protein
antibody 0.5β is likely to correspond to a solvent-exposed region in the native
gp120 molecule. Some residues of this region of gp120 are involved in 
co-receptor binding, and in discrimination between different chemokine
receptors utilized by the protein. Several highly variable residues in the V3 loop
limit the specificity of the 0.5β antibody, helping the virus to escape from the
immune system. The highly conserved GPG sequence might have a role in
maintaining the β-hairpin conformation of the V3 loop despite insertions,
deletions and mutations in the flanking regions.
Introduction
The binding of human immunodeficiency virus type 1
(HIV-1) to its target cells is mediated by the envelope
glycoprotein of the virus, gp120. Initially, gp120 binds to
CD4, a molecule found on the surface of both T cells and
macrophages, triggering conformational changes in gp120
that expose a binding site to either CCR5 or CXCR4
chemokine receptors. The virus infects the target cell only
after binding to one of these co-receptors and the HIV-1
phenotype is determined by the chemokine receptor it
recognizes. Macrophage-tropic strains use CCR5 for
fusion and entry into the target cell and are designated R5
viruses [1]. They are slow-replicating, non-syncytium-
inducing and are less sensitive to neutralization by soluble
CD4 and anti-V3 (V3, third hypervariable region of gp120)
antibodies than T-cell tropic strains. T-cell tropic strains
use CXCR4 (fusin) as a co-receptor [2–7] and are desig-
nated X4 viruses. X4 viruses are fast-replicating, syn-
cytium inducing and sensitive to neutralization by soluble
CD4 and by anti-V3 antibodies. Dual tropic viruses use
both CXCR4 and CCR5 and are designated R5X4 viruses.
Genetic analyses of the HIV-1 genome have demon-
strated that V3 contains major determinants responsible
for the phenotype of the virus and cell tropism. HIV-neu-
tralizing antibodies against V3 do not inhibit gp120
binding to CD4; however, they prevent fusion of the virus
with its target cell [8]. Recent experiments have shown
that human anti-V3 antibodies inhibit the binding of the
R5 gp120–CD4 complex to CCR5 co-receptor [9,10].
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Exchange of V3 from the IIIB strain (an X4 virus) with V3
of an R5 virus renders the virus infection susceptible to
inhibition by chemokines specific to CCR5 [11].
A cyclic V3 peptide corresponding to the complete V3
loop of an R5 virus binds to the membranes of monocyte-
derived macrophages at sub micromolar concentrations
[12]. The proteins involved in the binding were identified
as CCR5 and CD4, and it has been suggested that V3
forms a ternary complex with these two proteins [12].
Indeed, CD4 and CCR5 were found to be associated in a
3T3 cell line transfected to express CD4 and CCR5 and
this association is independent of gp120 or any other
ligand [13]. Cyclic V3 peptides of X4 viruses were found
to inhibit in a dose-dependent manner both antibody
binding to CXCR4 and infection by X4 viruses [14], pro-
viding evidence that cyclic V3 can interact with CXCR4
independently of other gp120 domains. Concentrations of
cyclic V3 peptides as low as 1–5 µM caused 50% inhibition
of HIV-1 infection [14]. Linear V3 peptides corresponding
to R5 and X4 viruses inhibit infection of CD4+ HeLa cells
expressing either CCR5 or CXCR4 or both [15]. All these
experiments demonstrate clearly that V3 interacts directly
with CCR5 and CXCR4 and is a significant component of
the gp120 interface involved in co-receptor binding. High-
affinity binding of gp120 to the chemokine receptors,
however, requires participation of other domains in gp120
such as the CD4i epitope [16].
Most neutralizing antibodies against HIV in infected indi-
viduals are directed against V3 [8]. Therefore, V3 has been
regarded as the principal neutralizing determinant (PND)
of HIV-1. Experimental data from different laboratories,
however, have shown that anti-V3 antibodies are not
important for the neutralization of R5 viruses [17–19].
This could be explained if the V3 loop of R5 viruses is
occluded in dormant viruses and become exposed for a
short period of time only after CD4 binding. Steric hin-
drance might prevent antibody binding to V3 once the
virus is bound to CD4. 
Three anti-V3 peptide antibodies in complex with HIV-1
MN strain (HIV-1MN) peptides were studied using X-ray
crystallography [20–22]. These antibodies recognized
small epitopes thus preventing the determination of the
V3 global conformation. Moreover, the V3 loop peptide
was found to have different conformations in complexes
with different anti-peptide antibodies [22]. The struc-
ture of the gp120 core in complex with a CD4 fragment
and an HIV-neutralizing antibody has been solved
recently using X-ray crystallography [23]. To enable crys-
tallization, however, the variable loops of gp120, includ-
ing V3, were truncated and the carbohydrates were
removed [23]. The 0.5β antibody used in the present
study is a potent strain-specific HIV-neutralizing anti-
body [24] raised against the entire gp120 of the HIV-1IIIB
strain. Neutralization of the free virus is obtained at 0.5β
concentration of 100 ng/ml, and full neutralization of
infected cells, as measured by syncytium inhibition, is
achieved at antibody concentrations as low as 50 µg/ml
[24]. The antibody 0.5β recognizes the 24-residue PND
peptide RP135 (NNTRKSIRIQRGPGRAFVTIGKIG,
in single-letter amino acid code) and the whole gp120
with comparable affinities of 2 × 108 M–1 and 7 × 107 M–1,
respectively [25]. Our previous 1H nuclear magnetic res-
onance (NMR) and binding studies of the 0.5β–RP135
peptide complex defined the boundaries of the determi-
nant recognized by the antibody as Lys5P–Ile20P (where P
denotes peptide) of RP135 [26,27]. The V3 peptide
P1053 (RKSIRIQRGPGRAFVTIG; the peptide residues
are numbered as Arg4P through Gly21P according to
RP135) comprises the complete 0.5β epitope and binds
to the antibody with almost the same affinity as RP135
[27]. The conformation of P1053 in complex with 0.5β
was determined using nuclear Overhauser effect spec-
troscopy (NOESY) difference spectra with the 0.5β
antigen-binding fragment (Fab) [28] and by isotope-fil-
tering experiments with uniformly 15N- and 13C-labeled
([U–15N,13C]) Fv [29]. The structure of the 0.5β-bound
P1053 peptide consists of two antiparallel strands linked
by a QRGPGR loop with a cis-proline type VI RGPG
turn [29]. Most recently, we proposed a model of the
0.5β–P1053 complex [30]. The peptide was docked into
the modeled antibody combining site on the basis of
seven intermolecular NOEs and one ‘mutant cycle’ dis-
tance restraint, and could be only approximately located
in the 0.5β binding site [30]. Unambiguous assignments
of the interacting tyrosine residues of the antibody were
not possible [30], thus preventing us from addressing
several structurally important issues.
The Fv is the smallest antigen-binding fragment of anti-
body molecules. It consists of the non-covalently associ-
ated variable domains of the light (VL) and heavy (VH)
chains, and contains six hypervariable complementarity
determining regions (CDRs) that form the antibody
binding site (L1, L2 and L3 are the CDRs of the light
chain and H1, H2 and H3 are the CDRs of the heavy
chain). The core of each domain consists of a highly con-
served framework, which forms the immunoglobulin fold.
Each of the CDRs excluding H3 folds into a restricted
number of canonical conformations classified based on the
crystal structures of numerous antibodies [31,32]. The Fv
fragments generally retain the specificity and affinity of
the parent antibody [33]. The molecular weight of the Fv
(~25 kDa) is half that of the Fab fragment and it is by far
more suitable for detailed NMR investigations. Here, we
describe the well-resolved solution structure of the
binding site of 0.5β Fv in complex with the V3 peptide
P1053. Possible implications of the V3 structure and its
solvent accessibility in gp120 for co-receptor binding and
the anti-V3 humoral immune response are discussed. 
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To the best of our knowledge, this is the first
antibody–peptide binding-site structure that has been
determined entirely from NMR restraints.
Results and discussion
0.5β Fv sidechain assignments and NOE interactions
The backbone and Cβ resonance assignments of the com-
plexed form of 0.5β Fv were reported earlier [34]. In this
study, the assignment of aliphatic sidechains was
achieved by the combined use of triple-resonance and
13C-edited NMR spectroscopy. The final extent of assign-
ments was 98.7% for the Fv backbone (excluding proline
15N) and 92.6% for the Fv aliphatic sidechains (excluding
labile 15N-bound sidechain protons). The combining site
of the complex is exceptionally rich in aromatic residues
with eight tyrosines, two histidines, a phenylalanine and a
tryptophan, all located at or near the Fv–peptide inter-
face. The 13C and 1H spin connectivities within the aro-
matic rings were established using TROSY (transverse
relaxation-optimized spectroscopy) experiments [35,36],
and the aromatic resonances were subsequently assigned
to specific residues using the Cβ(Cγ)CδHδ experiment
[37]. The residues Tyr32L, Tyr91H, Phe62L and His76L did
not provide Cβ–Hδ connectivities and were assigned using
(H)CCH-TROSY [36] and NOE connectivities in the
13C-separated NOESY spectra (the position of an amino
acid residue in the Fv sequence [31] is indicated by the
standard three-letter abbreviation followed by a number
and capital letter in superscript: L or H denoting light or
heavy chain residue, respectively). Dramatically improved
signal-to-noise ratios and narrower carbon line widths of
the slowly relaxing TROSY [35,36] component enabled us
to assign the sidechains of all 16 Fv tyrosines. The aro-
matic region of the 1H-13C TROSY [36] spectrum of the
0.5β Fv complexed with the unlabeled P1053 is shown in
Figure 1. The resonance assignments of the aromatic
sidechains were verified using 13C-edited NOESY experi-
ments. Strong NOEs between Hδ(Cδ) and the β-protons
of the aromatic residues helped to complete the assign-
ments based on J connectivities. The following aromatic
resonances remain unassigned: Cε/Hε, Cζ/Hζ of Phe71L, all
the resonances of Phe98L, Cε/Hε and Cζ/Hζ of Phe29H, and
the imidazole resonances of His95H.
The framework of the 0.5β light chain shares 96%
sequence homology with that of the 50.1 antibody [20]
light chain, whereas the heavy chain framework is 80%
homologous to that of the HYHEL-5 antibody [38]. The
long- and medium-range backbone NOEs detected in the
15N- and 13C-edited NOESY spectra of both Fv chains
were examined against distances in the 0.5β model [27],
rebuilt using the coordinates of 50.1 for the light chain [20].
The NOE and J-coupling data showed almost quantitative
agreement with the distances and dihedral angles of the
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Figure 1
2D 1H–13C TROSY [36] 800 MHz spectrum
of the 0.5β Fv complexed with the unlabeled
P1053 peptide recorded in D2O at 32°C
(10 h total acquisition time). The assignments
of the 0.5β Fv tyrosine residues are indicated.
Negative peaks are shown with dashed
contours and correspond to the resonances
of the carbon nuclei bound to an uneven
number of carbons (Cδ2 and Cδ1 of histidine
and tryptophan rings, respectively). The cross-
peaks of δ-Tyr32L and ε-Tyr95H are below the
contour levels of the plot.
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conserved part of the 0.5β model. For example, from 114
long- and medium-range intra-chain HN–HN, HN–Hα and
Hα–Hα contacts within a distance range of 3.5 Å that exist
in the framework region of 0.5β model, 98 were identified
as medium-to-strong cross-peaks in the NOESY spectra.
The remaining 16 cross-peaks could not be detected
because of overlap and/or exchange broadening of amide
resonances. The NMR data were used, therefore, to calcu-
late the structure of the Fv CDRs in complex with P1053,
assuming that the 0.5β model represents the structure of
the Fv framework with sufficient accuracy.
The intermolecular Fv–P1053 contacts were identified
using a combination of two approaches. Where possible,
these NOEs could be assigned using 13C- and/or 15N-fil-
tering in one of the spectral dimensions [29]. Unfortu-
nately, only ~75–80% isotopic labeling was achieved in
the Fv samples used for these measurements, seriously
compromising the quality of the filtered spectra. Many of
the peptide protons interacting with the antibody belong
to unlabeled methyl groups with favorable transverse
relaxation properties. We found it advantageous to substi-
tute the 1H evolution period in the isotope-edited
NOESY spectra by either constant-time or semi-constant
time evolution periods very similar to the well-known
BIRD (bilinear rotation decoupling) module [39] (see the
Materials and methods section). This resulted in sign
inversion of all those NOEs originating from 12C-bound
(P1053) protons as shown in Figure 2. The observed inter-
molecular NOEs between the 0.5β Fv CDRs and P1053
are summarized in Tables 1 and 2. The Fv heavy chain
interacts through hydrophobic and polar sidechains. H1
and H2 make the most significant contribution to the
interactions with the peptide. Thr31H γ-methyl and the
aromatic rings of His52H and Tyr53H interact extensively
with the hydrophobic sidechains of both β strands of
P1053. Unlike other antibody–ligand complexes solved
using X-ray crystallography, the H3 residues of 0.5β
provide only a small fraction of the antibody–ligand con-
tacts. Except for Asn92L, all the light chain residues inter-
acting with the peptide are hydrophobic (Tyr30aL [for the
CDR numbering nomenclature see Table 1], Tyr32L and
Phe96L). No NOE interactions between L2 and P1053
were observed. The P1053 epitope consists of residues
from Lys5P to Phe17P and the sidechain of Ile20P. Ile7P, cis-
Pro13P and Gly14P provide the most significant contribu-
tion to the observed peptide–antibody NOE contacts.
Interestingly, these are the most conserved V3 loop
residues among different HIV-1 strains [40].
The structure of the 0.5β binding site in complex with P1053
The structure calculations were carried out with 1138 dis-
tance and 80 dihedral restraints for P1053 and those Fv
residues permitted to move (see Materials and methods
section). Structural statistics for 40 structures of the 0.5β
388 Structure 2000, Vol 8 No 4
Figure 2
1H–1H strip plots of the F2-filtered 13C-NOESY spectrum (right panel),
the 13C-edited NOESY with the BIRD [39] t1 evolution period (central
and left panels) drawn at the frequencies of α-Thr31H, ε1-His52H and
α-Ile7P resonances and showing NOE interactions with Ile7P. The
F2-filtered 13C-NOESY spectrum features both intra-peptide and
Fv–peptide NOEs. Negative peaks are shown with dashed contours
and correspond to the Fv–peptide intermolecular NOEs in the
‘BIRD-supplemented’ spectra. 
Table 1
0.5β CDR canonical structures and the Fv–P1053 NOE contacts*.
CDR† Sequence Canonical structure (κ)
24 30 30a 30d 32 34
L1 KASQSVDYDGDSYMN 5
50 56
L2 AASNLES 1
89 97
L3 QQSNEDPFT 1
26 35
H1 GYTFTTYPIE 1
50 52a 53 65
H2 NFHPYSDDTNYNEKFKG 2A
95 99 100a 101
H3 HYGSAYAMDY ‘bulged’
*The CDR residues having NOE contacts with P1053 are shown in bold
and italicised; †CDR numbering follows that of Al-Lazikani et al. [71].
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binding site in complex with P1053 are presented in
Table 3. The backbone stereoview of 0.5β Fv in complex
with P1053 is shown in Figure 3. All Fv CDRs except H3
adopt standard canonical conformations (Table 1). The
coordinates of the ensemble of NMR structures differ sig-
nificantly (mean backbone root mean square deviation
[rmsd] > 1.0 Å) from the 0.5β model [27] in L1, H1 and H3.
The mean backbone rmsd values of the model versus 
the ensemble of NMR structures are 1.45 ± 0.12 Å,
1.06 ± 0.15 Å and 6.18 ± 0.05 Å for L1, H1 and H3, respec-
tively. The same Fv CDRs have all heavy-atom displace-
ments exceeding 2.0 Å (2.37 ± 0.21 Å, 2.58 ± 0.32 Å and
8.09 ± 0.09 Å for L1, H1 and H3, respectively) compared
with the Fv model. In L1 and H1 the atomic displacements
are predominantly local and concentrated at the flexible tip
of the L1 β hairpin (Asp30bL–Gly30cL) and around the begin-
ning of a helical turn in H1 (Tyr27H and Thr28H), whereas
H3 revealed a totally different and unexpected fold.
H3 conformations were recently classified based on
numerous antibody crystal structures [41]. According to
the proposed rules [41], H3 in 0.5β should adopt a regular
β-hairpin fold given that it has a neutral isoleucine residue
at position 94H (usually occupied by arginine or lysine that
form salt bridges with aspartic acid at position 101H).
Nevertheless, the 0.5β H3 has a ‘bulged torso’ [41] confor-
mation with a bulge at Asp101H as manifested by many
characteristic NOE contacts. The two antiparallel strands
of H3 are linked by a YGSAYA multiple-turn loop. This
fold enables a tight packing of hydrophobic sidechains.
The Tyr96H (H3) ring is packed against the ring of Tyr32H
(H2) and the sidechains of Ile94H and Tyr102H (both H3),
whereas the ring of Tyr100aH (H3) is packed against Tyr49L
(N-terminal to L2) as shown in Figure 4a. This packing
resembles the usually encountered conformation of
‘bulged torso’ H3 hairpins [41]. As a result of this packing,
Ala99H (H3) interacts with the bound peptide. The binding
site of 0.5β contains a contiguous hydrophobic surface con-
sisting of the sidechains of aromatic residues (Figure 4a),
alanine and proline. The bottom of the binding pocket is
located at the interface between the Fv light and heavy
chains and is comprised of Phe96L, Trp47H and Glu35H
sidechains. His95H and Ala99H form a rim on the right side
of the pocket limiting the space available for the peptide.
The sidechains of both β strands of P1053 are in contact
with H1, H2 and the H1–H2 interface (Figure 4a). The
GPG segment of P1053 is buried deeply at the center of
the binding pocket, with Pro13P interacting with the aro-
matic rings of Tyr30aL and Phe96L. The amide of Gly14P
most probably forms an intermolecular hydrogen bond
with the carbonyl of Ser95L (L3). The type VI RGPG turn
ensures a sharp reversal in the direction of the polypeptide
chain so that both preceding and succeeding residues of
the compact β hairpin of P1053 can interact with the anti-
body. The GPG segment of P1053 is sandwiched between
the aromatic rings of Tyr30aL, Tyr32L (both L1), Phe96L
(L3) and Tyr100aH (H3), and its conformation seems to be
crucial for efficient binding.
The combining site of 0.5β contains several negatively
charged sidechains, whereas the P1053 peptide contains
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Table 2
The Fv–P1053 NOE contacts*.
Peptide residues Fv contact residues
Lys5 Tyr53 (H2)
Ser6 Thr31 (H2)
Ile7 Thr30 (H1), Thr31 (H1), His52 (H2),
Tyr53 (H2), Ser54 (H2)
Arg8 His52 (H2)
Ile9 His52 (H2)
Gln10 Pro33 (H1), His52 (H2), Asn58 (H2)
Arg11 Asp56 (H2)†
Gly12 Phe96 (L3)
Pro13 Tyr30a (L1), Asn92 (L3), Phe96 (L3)
Gly14 Tyr32 (L1), Asn92 (L3), Phe96 (L3), Ala99 (H3)
Arg15 Ala99 (H3)
Ala16 Ala99 (H3)
Phe17 Thr31 (H1), Tyr32 (H1), Ala99 (H3)
Ile20 Tyr53 (H2)
*The P1053 residues having backbone–backbone NOE contacts with
the Fv are shown in bold and italicised; †The Arg11P–Asp56H contact
was inferred from earlier mutational studies (see text).
Table 3
Structural statistics for the set of 40 structures of the 0.5β
Fv–P1053 binding site*.
Restraints and violations
Intra-CDR medium and long-range restraints 442
Inter-CDR distance restraints 161
Intra-P1053 distance restraints† 201
Intermolecular Fv–P1053 distance restraints 92
P1053 dihedral restraints† 11
Fv CDR φ angle restraints 47
Fv CDR χ1 angle restraints 22
Maximum individual NOE violation (Å) 0.34
Average rmsd of NOE violations (Å) 0.022 ± 0.003
Average rmsd of dihedral violations (°) 0.62 ± 0.112
Average rmsd from ideal covalent geometry
Bond lengths (Å) 0.0026 ± 0.0002
Bond angles (º) 0.4800 ± 0.0223
Improper angles (º) 0.4375 ± 0.0348
Pair-wise rmsd values‡
Backbone atoms (Å) 0.67 ± 0.12
All heavy atoms (Å) 1.44 ± 0.17
P1053 backbone atoms (Å) 0.92 ± 0.23
P1053 all heavy atoms (Å) 1.89 ± 0.36
P1053 K5-I7 and F17-I20 all heavy atoms (Å) 1.24 ± 0.32
P1053 RGPGR loop all heavy atoms (Å) 1.66 ± 0.60
*The reported structural statistics were calculated for the 0.5β Fv
CDR and P1053 residues that were allowed to move during structure
calculations (see the Materials and methods section). †Taken from
[29] (see the Materials and methods section). ‡Calculated for the
structures superimposed for the exact fit of the framework backbone
atoms (see Figure 3).
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four arginines and one lysine. The binding of the
Arg4→Lys and Arg11→Lys mutants of P1053 to 0.5β is
comparable to that of the unmodified peptide [28]. The
conservative Arg8→Lys, Arg8→His and Arg15→Lys
mutations reduced the binding by more than two orders of
magnitude [28] indicating that Arg8P and Arg15P sidechains
are critical for interactions with 0.5β. Indeed, as shown in
Figure 5 Arg8P and Arg15P form the largest contact areas
with the antibody in the mean structure, whereas the
sidechain of Arg11P is among the most exposed to the
solvent in the bound P1053. Arg4P is completely outside
the epitope recognized by 0.5β. The sidechain protons of
Arg15P and Arg8P could not be definitely assigned from the
isotope-filtered spectra [29]. Therefore, no NOE con-
straints were used for the sidechains of these residues. It
was found that when the backbone dihedral restraints
determined from solid-state NMR data [42] are used for
Arg15P, its sidechain invariably points towards and most
probably forms a buried salt bridge with the carboxyl of
Glu35H. In the calculated structures, the methylene
protons of Arg15P interact extensively with the aromatic
ring of Phe96L (L3) and with the hydrophobic sidechains
of Pro33H (H2) and His95H (H3) of 0.5β. The sidechain of
Arg8P is almost completely buried in the resulting struc-
tures. The methylene protons of Arg8P have extensive
intra-peptide interactions with the ring of Phe17P and with
the methylene protons of Arg15P. The guanidinium group
of Arg8P approaches the surface close to the H1–H3 inter-
face and could potentially interact through hydrogen
bonds with the backbone carbonyl oxygens of Pro33H (H2)
and/or His95H (H3). The structural reasons for the uncom-
pensated and partially buried charge in the intermolecular
interface are unclear. The existence of a previously postu-
lated intermolecular Arg11P–Asp56H solvent-exposed salt-
bridge [30] could not be directly corroborated by the
present NMR data. The sidechain of Asp56H is disordered
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Figure 3
Stereoview superposition of 40 0.5β
Fv–P1053 complex backbone structures. The
Fv framework regions are superimposed
exactly, as their coordinates were fixed during
the structure calculations (see the Materials
and methods section and text). The light and
heavy chains of the Fv and the P1053 peptide
are colored red, green and blue, respectively.
Figure 4
The structure of the 0.5β–P1053 binding
interface. (a) A space-filling representation of
the 0.5β binding site (mean 0.5β Fv–P1053
structure). The 0.5β residues are colored as
follows: aromatic, green; acidic, red; and
basic, blue. The bound P1053 peptide
backbone is shown as a light blue ribbon.
Several of the most extensively interacting
sidechains of the peptide are shown in yellow
and labeled in black. (b) The face of P1053
buried by the 0.5β antibody upon binding. The
residues of the peptide in contact with the
antibody and those spatially adjacent to them
are labeled.
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as judged by strong 3JHαHβ couplings to both of itsβ-protons. It is possible that the surface salt bridge is not
thermodynamically stable and is destroyed at the slightly
elevated temperatures used for NMR measurements. The
sidechain of Arg11P is in close proximity to the carboxyl of
Asp56H, however, and the distance constraint between
them did not perturb the resulting structures.
The mean atomic displacements of the P1053 peptide in
the 0.5β Fv–P1053 ensemble of structures versus the
bound peptide in the averaged coordinates of the recently
calculated Fab–P1053 model [30] are 8.60 ± 0.33 Å and
10.2 ± 0.43 Å for the backbone and all heavy atoms,
respectively. These differences do not arise from differ-
ent conformations of the peptide itself, however, given
that the same intra-peptide restraints [30] were used in
both studies. These differences rather represent a signifi-
cant shift in the position of the bound P1053 compared
with the proposed model, primarily because of an order-
of-magnitude increase in unambiguously identified inter-
molecular contacts in the Fv–P1053 complex (5.1 versus
0.4 per peptide residue). Given that most of the intermol-
ecular contacts involve the sidechain atoms of P1053, a
significantly better definition of the bound peptide
sidechains was achieved (Table 2). The more accurate
positioning of the peptide within the 0.5β combining site
structure and a significantly better definition of both the
Fv CDRs and P1053 coordinates allowed us to address
several biologically important issues concerning the V3
structure and function.
Anti-gp120 0.5β antibody versus antipeptide antibodies
The surface areas buried upon P1053 binding to the anti-
gp120 0.5β antibody are 601 and 743 Å2 for the 0.5β Fv
and the P1053 peptide, respectively. The surface area
contributed by 0.5β is therefore on average 13% and 28%
larger than that contributed by the antipeptide antibodies
50.1 [20] and 59.1 [21], respectively, and is close to that
reported for the antibody 58.2 [22]. The peptide contribu-
tion exceeds that of 50.1, 59.1 and 58.2 complexes by 56%,
73% and 29%, respectively. The P1053 interacting
surface, consisting of all peptide residues except for Arg4P,
Val18P, Thr19P and Gly21P, is more extensive than that
observed in the X-ray studies of the complexes of V3MN
peptides with antipeptide antibodies and is larger than the
combination of the peptide epitopes recognized by 50.1
and 59.1 antipeptide Fabs [20,21]. The peptide orienta-
tions within the binding pocket also differ substantially.
For example, P1053 interacts extensively with H1 and the
H1–H2 interface (Table 2; Figure 4a), quite unlike the
peptides studied using X-ray crystallography [20–22].
V3 peptides are flexible when they are free in solution
and therefore antibodies raised against such peptides rec-
ognize different V3 conformations [22]. The conformation
of V3 in native gp120 should be considerably more
restricted. V3-directed antibodies raised against the entire
envelope glycoprotein recognize the native V3 conforma-
tion and are able to induce this conformation in flexible
V3 peptides. We cannot exclude the possibility that the
loop at the tip of the β hairpin in gp120 exhibits some
conformational flexibility. In this case 0.5β might select
one out of a family of structures of this loop or even
induce a different structure into the QRGPGR sequence
in P1053. Nevertheless, our working model is based on
the assumption that the V3 loop is structured in intact
gp120 and manifests a similar structure when bound to
the 0.5β antibody.
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Figure 5
Surface characterization of the bound P1053
peptide. Black bars represent the solvent
surface accessibility of the residues of bound
P1053 (in % of the total van der Waals
surface of the residue). Grey bars represent
the relative contribution of each peptide
residue to the Fv–P1053 contact surface area
(in % of the total contact surface area
contributed by the peptide).
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The V3 surface buried upon antibody binding
The peptide surface interacting with the antibody is
depicted in Figure 4b. This side of the V3 loop is most
likely to be exposed in the free gp120 that was used as an
immunogen. As V3 is involved in the interaction of gp120
with the chemokine receptors found on T cells and
macrophages, this exposed surface probably contains
residues contributing to co-receptor binding. The V3
loops of M-tropic and T-tropic viruses share considerable
sequence homology. A switch in the phenotype of the
virus from syncytium-inducing to non-syncytium-inducing
or vice versa was found to depend on the charge of the
residues at positions 306 (Ser6P in P1053), 320 and 324
[43]. The last two residues are absent from P1053. Later
on, it was found that the phenotype is determined by the
chemokine receptor used by the virus for fusion and entry,
either CCR5 or CXCR4 [1]. Cyclic V3 peptides bind to
the corresponding co-receptors at micromolar concentra-
tions [13,15]. A single Asp320→Arg mutation in a V3
peptide transformed it from an M-tropic to a T-tropic
virus inhibitor [15]. These findings indicate that V3 con-
tains a significant determinant directly interacting with
the chemokine receptor regardless of the receptor type.
Residues Lys5P, Ile7P and Phe17P of V3 are important for
CCR5 utilization [44], and together with Ser6P found to be
important for the co-receptor choice [15], form a continu-
ous surface in P1053 (Figure 4b). Arg15P, also involved in
CCR5 utilization [44], is separated from this patch by the
sidechain of Arg8P. Residue 320 of V3 is outside the
epitope recognized by 0.5β. It is conceivable that in native
V3, the sidechain of this residue, critical for the selection
of the co-receptor type [15], is adjacent to the patch
formed by Lys5P, Ser6P, Ile7P and Phe17P. It is noteworthy
that a positively charged residue (usually lysine), an
isoleucine, a positively charged residue (usually arginine)
and a phenylalanine or another hydrophobic residue are
highly conserved at gp120 positions corresponding to
peptide residues 5, 7, 15 and 17, respectively [40].
The surface of V3 between the patch involved in co-
receptor binding and the highly conserved GPG region
contains variable residues. Gln10P is part of a two-residue
insertion appearing in only ~10% of all HIV-1 isolates.
Arginine appears at position 8 only in ~11% of the HIV-1
isolates. Both Gln10P and Arg8P form large contact areas
with the antibody surface as shown in Figure 5. The vari-
ability of these protruding residues in the gp120 molecule
is probably responsible for the induction of strain-specific
antibodies. These hot spots of variable residues very close
to the conserved binding site for the chemokine receptors
help the virus to evade the immune system.
The role of the GPG segment, the most conserved
sequence in V3 [40], remains unclear. As this segment
interacts with the antibody, it is most likely to be exposed
in the gp120 molecule. In addition to what has been sug-
gested previously [29], it is plausible that its function would
be to stabilize the β-hairpin conformation by forming a
reverse turn. Although the β hairpin was not observed for
the MN strain [20–22], we previously suggested that it is
common to most HIV-1 isolates [28,29]. A one-residue shift
in the β turn in P1053 in comparison to MN peptides [29]
and a formation of a six-residue rather than a four-residue
loop accommodate the two-residue insertion that is typical
of HIV-1IIIB strain while conserving the location of theβ strands within V3. The conformation of the turn in the
GPGR sequence at the tip of the V3 peptide was found to
be different in the HIV-1MN and HIV-1IIIB strains [29]. It is
reasonable that the turn connecting the two β strands of
P1053 influences the spatial orientation and exposure of
the V3 sidechains interacting with the co-receptors and that
of the highly variable residues that help the virus to escape
from the immune system.
The peptide residues Val18P and Thr19P do not have any
contacts with the antibody and, surprisingly, Ile9P and
Ala16P have only minor contacts with 0.5β despite their loca-
tion in a central region of the epitope (Figure 5). The
involvement of Val18P, Thr19P and Ile9P in many interactions
within the bound peptide, the lack of interactions with the
antibody and the hydrophobic character of Val18P and Ile9P
suggest that they are buried in the free gp120 molecule.
Biological implications
The envelope glycoprotein of human immunodeficiency
virus type-1 (HIV-1), consisting of an external domain,
gp120, and a transmembrane domain, gp41, is the most
important target for the humoral immune response that
is elicited by an anti-HIV vaccine. The principal neu-
tralizing determinant of gp120 is located within its third
hypervariable region (V3 loop). Several HIV-1 V3
residues important for co-receptor choice were identified
by examining naturally occurring mutants and using
site-directed mutagenesis. Recently, several residues at
the center of V3 were shown to be involved in
chemokine receptor utilization. In a number of cases,
anti-HIV antibodies inhibited V3–chemokine-receptor
binding. The V3 loop was deleted from the
gp120–CD4–antibody complex solved recently using X-
ray crystallography. No direct structural information is
therefore available on V3 and V3–antibody interactions.
The 0.5β antibody used in the present study was elicited
against the gp120 molecule of the HIV-1IIIB strain.
Given that the whole gp120 was used as an immunogen,
the interactions of 0.5β with the V3 peptide should serve
as a reliable model for the interactions between the
intact gp120 and anti-IIIB antibodies. Our nuclear mag-
netic resonance (NMR) results suggest that the surface
of the V3 peptide in contact with the antibody is likely to
correspond to a solvent-exposed region in the native
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gp120 molecule. The conformation of the V3IIIB peptide
bound to 0.5β consists of two antiparallel β strands
linked by a QRGPGR (in single-letter amino acid code)
loop. The solution structure of the 0.5β binding site in
complex with P1053 provides insight into a component
of the chemokine receptor-binding interaction with
gp120. High-affinity binding of gp120 to the chemokine
receptor probably involves V3 residues down-stream
from the 0.5β epitope as well as residues in the con-
served and occluded CD4i epitope. The highly variable
and protruding residues next to the chemokine receptor
binding site are likely to be included in the epitope recog-
nized by antibodies against this site. Mutations in these
variable residues limit the specificity of the neutralizing
antibody and help the virus escape from the immune
system.
The structure of the binding site of the anti-gp120 anti-
body in complex with the V3 peptide P1053 can be used
to analyze the structural and functional implications of
sequence variations on co-receptor usage and antibody
specificity. This structure might help to construct a
cocktail of V3 peptides that will induce a broadly neu-
tralizing immune response. In the absence of the three-
dimensional structure of the chemokine receptor
involved in HIV-1 infection, the structure of V3 might
be useful to design anti-HIV-1 drugs that target this
receptor.
Materials and methods
Fv isotope labeling and sample preparation
The peptides were chemically synthesized on an Applied Biosystem
430A automated peptide synthesizer and purified by using high perfor-
mance liquid chromatography (HPLC) as described elsewhere [26,27].
The 0.5β Fv was expressed in E. coli strain BL21(DE3) [45].
[U–13C,15N]-Fv was obtained using an efficient and cost-effective pro-
tocol. The cells were grown for 16 h at 37°C on 2xTY medium, contain-
ing glucose 1% (w/v), ampicillin (100 µg/ml) and chloramphenicol
(25 µg/ml). The cell pellet was washed twice with 50 mM NaCl solution
and then resuspended in isotope-enriched Celtone rich medium
(Martek Biosciences Corp., US) supplemented with 0.5% 13C-labeled
glycerol. After incubation for 45 min at 30°C, induction was performed
by adding 1 mM IPTG (isopropylthio-β-D-galactoside) followed by incu-
bation for 16–18 h at 30°C. Next, 350 mM NaCl and a mixture of the
following protease inhibitors were added to the cooled broth: aprotinin
(2 µg/ml), EDTA (5 mM), leupeptin (2 µg/ml), pepstatin (1 µg/ml),
PMSF (100 µg/ml), TPCK (100 µg/ml), benzoamidine (1 mM), iodoac-
etamide (1 mM) and N-ethylmaleimide (1 mM). This extensive use of
protease inhibitors alleviated the problem of post-expression proteolysis
of the correctly folded Fv. The Fv was purified on a set of three
columns, including Sepharose CL-4B, DE-52 anion exchange, and an
affinity column prepared with P1053 cross-linked to Sepharose CL-4B,
and then additionally purified by HPLC on an Ultropac column (TSK
G3000SWG) with a 250 mM phosphate elution buffer. A typical yield
of ~10 mg of [U–15N,13C]-Fv per liter of Celtone medium was achieved.
The Fv–peptide complexes (27.6 kDa) were prepared by addition of a
~20% molar excess of lyophilized peptide to a dilute Fv solution
(~0.05 mM), dialysis against 50 mM NH4HCO3 to remove peptide
excess and lyophilization. Three samples of the 0.5β Fv–peptide
complex were used: two 0.6 mM samples of [U–13C,15N]-Fv com-
plexed with the unlabeled P1053 in H2O (pH 7.1) and 0.75 mM
[U–13C,15N]-Fv complexed with the unlabeled P1053 in D2O (pD 7.2,
uncorrected for the isotope effect). The samples contained 10 mM
sodium phosphate buffer with 0.05% NaN3 to prevent bacterial growth,
and were placed in 5 mm Shigemi cells (Shigemi Inc., US).
NMR spectroscopy
All NMR spectra were recorded at 32°C on Bruker DRX800 and
DMX600 spectrometers equipped with z-gradient triple-resonance
probes and BTO temperature regulation units. The spectra were
processed with NMRPipe/NMRDraw [46], and analyzed using the
NMRView [47] program and in-house scripts. The following three-
dimensional (3D) experiments were used to assign the Fv aliphatic
sidechain resonances unassigned earlier: HBHA(CBCACO)NH [48],
C(CO)NH [49], HACACO [50], HC(C)H-COSY [51] and HC(C)H-
TOCSY (total correlation spectroscopy) [52]. Substantial chemical
shift degeneracy of α-carbons in the 13C-edited spectra could be
partially resolved using 3D HBHA(CBCA)CO(CA)HA [53] and
CBCACO(CA)HA [54] data sets. The assignment of aromatic
sidechains was accomplished using 2D 13C-TROSY [36], 3D
(H)CCH-TROSY [36], Cβ(Cγ)CδHδ [37], and HC(C)H-TOCSY [52]
optimized for aromatic sidechains. The following NOESY spectra were
acquired: 3D NOESY-15N-HSQC (heteronuclear single quantum cor-
relation) with water flip-back and the use of radiation damping during
the 80 ms mixing period [55–57], 3D NOESY-15N-TROSY [58] with
34 and 84 ms mixing periods using Fv with selective chain labeling
[34], 3D NOESY-13C-HMQC (heteronuclear multiple quantum coher-
ence spectroscopy) [59,60] in D2O with a 76 ms mixing period, 3D
NOESY-13C-HMQC [59,60] with an 80 ms mixing period optimized
for the aromatic sidechains, and 4D 13C/13C-separated NOESY [61]
in D2O with an 80 ms mixing period. A series of short 15N-HSQC [62]
spectra were used to identify slowly exchanging Fv amide protons.
In the ‘BIRD-supplemented’ NOESY spectra (see text), the hetero-
nuclear one-bond couplings were allowed to evolve for the whole con-
stant-time period (adjusted to slightly more than ~1/1JX–H to ensure
sufficient resolution in 1H dimension) by simultaneous 180° pulses on
1H and X channels. The constant-time t1 evolution compromised
signal-to-noise of these spectra, but strong and medium NOEs originat-
ing from peptide protons could be observed. The unlabeled part of the
antibody provides an attenuating (negative) component to positive
NOEs originating from 13C-bound protons. This BIRD-supplemented
NOESY thus only complemented, but not substituted, conventional
13C-edited spectra. Obviously, this approach is inapplicable for levels
of isotopic enrichment much lower than those used in the present
study, since 12C-bound protons possess significantly longer T2 values
than 13C-bound ones and can invert the peaks of a partially labeled
component. The BIRD-supplemented 13C-edited NOESY spectra were
collected for the aliphatic and aromatic regions separately.
The quantitative J-spectroscopy approach [63] was employed to
measure J couplings. The 3JHNHα coupling constants were measured
from 3D HNHA [64] experiments recorded for the Fv molecules with
chain specific labeling [34] using water flip-back and an 18 ms
dephasing period. The values of 3JHNHα obtained from peak intensity
ratios were scaled by a factor of 1.20 to account for fast spin-flips
during the dephasing period. 3JHαHβ couplings were derived where
possible from a 3D HACAHB [65] experiment recorded in D2O. 2D
HN(CG) and HN(CO)CG constant-time spin-echo difference experi-
ments [66] were used to determine aromatic 13Cγ–15N and 13Cγ–13C′J
couplings, respectively. 2D spin-echo difference 13C-HSQC spectra
[67] were used to measure 13Cγ–15N and 13Cγ–13C′ J couplings of
residues possessing γ-methyls.
Structure calculations
The X-PLOR 3.851 program [68] was used for structure calculations
with standard simulated annealing protocols. All the peptide residues
and the Fv CDR loops together with three N-terminal residues of both
Fv chains (Asp1L–Val3L, Ser26L–Met33L, Tyr49L–Asn53L, Ser91L–Phe96L,
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Gln1H–Gln3H, Gly26H–Glu35H, Asn50H–Asn58H, Ile94H–Tyr102H) were
allowed to move (26% of the whole Fv molecule), while the framework
of 0.5β Fv was held fixed. The N termini of both VL and VH are in close
spatial proximity to the CDRs of the Fv and were included in the calcu-
lations. The lists of constraints included the intermolecular constraint
between the guanidinium group of Arg11P and the carboxyl of Asp56H
from the previous mutational studies [30], and the φ and ψ dihedral
constraints of Arg15P derived from the solid-state NMR data [42]. The
rest of the intra-peptide distance and dihedral restraints derived from
isotope-filtering and isotope-editing studies [29] were used without
changes. The structures of the bound P1053 [29] and the 0.5β Fv
model were used as the starting coordinates. After simulated annealing
calculations, the structures were minimized using 800-step Powell min-
imization with full Lennard–Jones potential representation and the elec-
trostatic term included. An NOE force constant of 50 kcal/mole was
used throughout the calculations. R–6 distance averaging for degener-
ate atoms was employed. The NOE cut-off for acceptable structures
was set to 0.4 Å. The calculated structures were analyzed for covalent
geometry and NOE violations with Aqua/Procheck-NMR [69] and
MOLMOL [70] programs and displayed with InsightII (MSI Corp., US).
Accession numbers
Coordinates of the average minimized 0.5β Fv–P1053 complex struc-
ture were deposited in the Brookhaven Protein Data Bank with acces-
sion code 1nqz.
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